PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Subramanian, P.* ; Hampe, J.* ; Tacke, F.* ; Chavakis, T.

Fibrogenic pathways in metabolic dysfunction associated fatty liver disease (MAFLD).

Int. J. Mol. Sci. 23:6996 (2022)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The prevalence of nonalcoholic fatty liver disease (NAFLD), recently also re-defined as metabolic dysfunction associated fatty liver disease (MAFLD), is rapidly increasing, affecting ~25% of the world population. MALFD/NAFLD represents a spectrum of liver pathologies including the more benign hepatic steatosis and the more advanced non-alcoholic steatohepatitis (NASH). NASH is associated with enhanced risk for liver fibrosis and progression to cirrhosis and hepatocellular carcinoma. Hepatic stellate cells (HSC) activation underlies NASH-related fibrosis. Here, we discuss the profibrogenic pathways, which lead to HSC activation and fibrogenesis, with a particular focus on the intercellular hepatocyte-HSC and macrophage-HSC crosstalk.
Impact Factor
Scopus SNIP
Altmetric
6.208
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Fibrosis ; Hepatic Stellate Cells ; Hepatocyte ; Macrophage ; Metabolic Associated Fatty Liver Disease ; Nonalcoholic Fatty Liver Disease ; Nonalcoholic Steatohepatitis
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 1661-6596
e-ISSN 1422-0067
Zeitschrift International Journal of Molecular Sciences
Quellenangaben Band: 23, Heft: 13, Seiten: , Artikelnummer: 6996 Supplement: ,
Verlag MDPI
Verlagsort Basel
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Pancreatic Islet Research (IPI)
POF Topic(s) 90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502600-008
Förderungen Federal Ministry of Education and Research
DOI 10.3390/ijms23136996
WOS ID WOS:000824189100001
PubMed ID 35805998
Erfassungsdatum 2022-10-27
[➜Korrektur melden]